- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00646360
Effects of Prenatal DHA Supplements on Infant Development
June 6, 2022 updated by: Usha Ramakrishnan, Emory University
This research study research is about the significance of polyunsaturated fatty acids (PUFAs) for human development.
Specifically, the study team will assess the effect of docosahexanoic acid (DHA) supplementation during pregnancy on infant growth and development through a randomized controlled intervention trial in Cuernavaca, Mexico.
This is a collaborative effort between the Rollins School of Public Health, Emory University, the Instituto Nacional de Salud Publica (INSP) and the Instituto Mexicano del Seguro Social (IMSS), Cuernavaca, Mexico.
Pregnant women attending the IMSS General Hospital I are recruited between 18-22 weeks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
The main study outcomes include a) birth outcomes: birth size, gestational age, cord blood levels of DHA and neurodevelopment b) maternal blood and breast milk DHA levels at 1 and 3 months post-partum, c) postnatal growth and development during the first 5 years of age and d) infant DHA status at 3, 12 and 18 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This research study is about the significance of polyunsaturated fatty acids (PUFAs) for human development.
Specifically, the study team will assess the effect of docosahexanoic acid (DHA) supplementation during pregnancy on infant growth and development through a randomized controlled intervention trial in Cuernavaca, Mexico.
This is a collaborative effort between the Rollins School of Public Health, Emory University, the Instituto Nacional de Salud Publica (INSP) and the Instituto Mexicano del Seguro Social (IMSS), Cuernavaca, Mexico.
Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
The main study outcomes include a) birth outcomes: birth size, gestational age, cord blood levels of DHA and neurodevelopment b) maternal blood and breast milk DHA levels at 1 and 3 mo post-partum c) postnatal growth and development during the first 5 years of age and d) infant DHA status at 3, 12 and 18 mo.
All data collection is carried out at the study headquarters (IMSS) except for home environment that is assessed during home visits.
Physical growth (length, weight, and head circumference) and infant and child development (visual and auditory evoked potentials, visual attention, Bayley scales of infant development, McCarthy child development score, Hearts and Flowers stroop test, and other computerized child development tests) are measured at birth, 1, 3, 6, 9, 12, 18, 24, 36 months and at 4 and 5 years of age by trained workers.
Data are also obtained on socioeconomic status, obstetric history, maternal diet, anthropometry and intelligence, quality of home environment and infant feeding practices.
Data analysis will include group comparisons (intent-to-treat) after ensuring effectiveness of randomization, and structural equation modeling to examine the various pathways by which DHA supplementation during pregnancy affects child growth and development.
The findings of this project will contribute significantly to our understanding of the functional consequences of DHA supplementation during pregnancy.
Study Type
Interventional
Enrollment (Actual)
1094
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Morelos
-
Cuernavaca, Morelos, Mexico
- IMSS General Hospital I
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 18-22 weeks pregnant (based on last menstrual period)
- 18 - 35 years old
- Resident of Cuernavaca who intends to deliver at the IMSS General Hospital I and remain in the area for the 2 years following recruitment
- Intends to predominantly breastfeed infant until 3 months of age
- Agrees to participate with informed consent
Exclusion criteria
- High risk pregnancy: If documented in the clinical record at recruitment and will include history and prevalence of abruptio placentae, any serious bleeding episode in the current pregnancy, gestational diabetes, pregnancy induced hypertension, maternal toxoplasmosis infection during pregnancy, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use.
- Lipid metabolism (hyperlipidemia) and/or absorption disorders
- Regular intake of fish oil or DHA supplements during pregnancy
- Chronic use of medication for illnesses like epilepsy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DHA arm
Docosahexonic acid (DHA) (400 mg/day).
Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
|
400 mg/d of docosahexanoic acid (DHA) during pregnancy
Other Names:
|
Placebo Comparator: Placebo arm
Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
|
2 tablets daily during pregnancy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Birth size
Time Frame: Birth
|
Birth size will be determined by measuring the newborn, a baby's length is measured from the top of their head to the bottom of one of their heels.
|
Birth
|
Gestational age
Time Frame: Birth
|
Gestational age is measured in weeks, from the first day of the woman's last menstrual cycle to the current date.
|
Birth
|
Changes in visual evoked potentials
Time Frame: 3 and 6 months of age
|
Visual evoked potential (VEP) is an electrical signal emanated from the brain while a visual stimulus is presented to the subject in a time locked manner.
The VEP can be used as a diagnostic tool to detect ocular diseases in patients with visually impaired.
VEP response can also be used to detect eye diseases like glaucoma, diabetic retinopathy, multiple sclerosis, ocular hypertension, loss of peripheral (side) vision, macular degeneration and color blindness.
|
3 and 6 months of age
|
Changes in infant weight
Time Frame: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Infant weight is measured in kilograms (kg) and weight is measured in the hospital and at all check-ups.
|
Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Changes in infant height
Time Frame: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Infants will be measured in the hospital and at all check-ups.
Height is measured in centimeters (cm).
|
Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Changes In infant head circumference
Time Frame: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Head circumference or OFC [occipital frontal circumference] is measured over the most prominent part on the back of the head (occiput) and just above the eyebrows (supraorbital ridges).
This can be translated to mean the largest circumference of the head.
Head circumference is measured in centimeters (cm).
|
Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Changes in auditory evoked potentials
Time Frame: 1 and 3 months of age
|
A brainstem auditory evoked response (BAER) test measures how the brain processes the sounds a person hears.
The BAER test records the subject's brainwaves in response to clicks or other audio tones that are played for them.
|
1 and 3 months of age
|
Changes in child development score
Time Frame: 1, 1.5 and 5 years of age
|
The Bayley Scales of Infant Development -II are used to assess child development during the first two years of life while The McCarthy Scales of Children's Abilities (MSCA) is a psychological instrument for young children that measures cognitive ability in six domain areas: Verbal, Perceptual-Performance, Quantitative, General Cognitive, Memory, and Motor at age 5 y.
|
1, 1.5 and 5 years of age
|
Changes in Hearts and Flowers Stroop Test
Time Frame: 5 years of age
|
This tests working memory, response inhibition, and task switching/cognitive flexibility .
The task requires participants to press a response button that is either on the same side (congruent) or opposite side (incongruent) of an image.
When children see an image of a heart, they are instructed to press the corresponding directional arrow button on a keyboard.
When children see an image of a flower, they are instructed to press the opposite directional arrow button on the keyboard .
The task consists of three separate levels that contain only congruent trials (12 trials total), only incongruent trials (12 trials total), and mixed congruent and incongruent trials respectively (33 trials total).
Images are presented on a computer monitor.
Before both the congruent and incongruent trial blocks, a training period is administered which consists of 5 trials.
The child is unable to advance to the next question until they respond correctly.
|
5 years of age
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes Immune function
Time Frame: first 6 months of life
|
first 6 months of life
|
|
Changes in Morbidity
Time Frame: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Changes in morbidity (health) factors will be assessed.
|
Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age
|
Cognitive outcomes at age 7 years of age
Time Frame: At 7 year follow up
|
The cognitive intelligence test WAIS-IV offers compound scores that reflect the intellectual functioning of 4 cognitive areas (verbal understanding, perceptive reasoning, working memory and processing speed).
It also offers a compound score that reflects intellectual aptitude in general (Intelligence quotient).
|
At 7 year follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Usha Ramakrishnan, Ph.D., Emory University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gonzalez Casanova I, Schoen M, Tandon S, Stein AD, Barraza Villarreal A, DiGirolamo AM, Demmelmair H, Ramirez Silva I, Feregrino RG, Rzehak P, Stevenson I, Standl M, Schnaas L, Romieu I, Koletzko B, Ramakrishnan U. Maternal FADS2 single nucleotide polymorphism modified the impact of prenatal docosahexaenoic acid (DHA) supplementation on child neurodevelopment at 5 years: Follow-up of a randomized clinical trial. Clin Nutr. 2021 Oct;40(10):5339-5345. doi: 10.1016/j.clnu.2021.08.026. Epub 2021 Sep 11.
- Tandon S, Gonzalez-Casanova I, Barraza-Villarreal A, Romieu I, Demmelmair H, Jones DP, Koletzko B, Stein AD, Ramakrishnan U. Infant Metabolome in Relation to Prenatal DHA Supplementation and Maternal Single-Nucleotide Polymorphism rs174602: Secondary Analysis of a Randomized Controlled Trial in Mexico. J Nutr. 2021 Nov 2;151(11):3339-3349. doi: 10.1093/jn/nxab276.
- Barrios PL, Garcia-Feregrino R, Rivera JA, Barraza-Villarreal A, Hernandez-Cadena L, Romieu I, Gonzalez-Casanova I, Ramakrishnan U, Hoffman DJ. Height Trajectory During Early Childhood Is Inversely Associated with Fat Mass in Later Childhood in Mexican Boys. J Nutr. 2019 Nov 1;149(11):2011-2019. doi: 10.1093/jn/nxz157.
- Gonzalez-Casanova I, Stein AD, Barraza-Villarreal A, Feregrino RG, DiGirolamo A, Hernandez-Cadena L, Rivera JA, Romieu I, Ramakrishnan U. Prenatal exposure to environmental pollutants and child development trajectories through 7 years. Int J Hyg Environ Health. 2018 May;221(4):616-622. doi: 10.1016/j.ijheh.2018.04.004. Epub 2018 Apr 22.
- Gutierrez-Delgado RI, Barraza-Villarreal A, Escamilla-Nunez C, Hernandez-Cadena L, Garcia-Feregrino R, Shackleton C, Ramakrishnan U, Sly PD, Romieu I. Effect of omega-3 fatty acids supplementation during pregnancy on lung function in preschoolers: a clinical trial. J Asthma. 2019 Mar;56(3):296-302. doi: 10.1080/02770903.2018.1452934. Epub 2018 Apr 4.
- Gutierrez-Gomez Y, Stein AD, Ramakrishnan U, Barraza-Villarreal A, Moreno-Macias H, Aguilar-Salinas C, Romieu I, Rivera JA. Prenatal Docosahexaenoic Acid Supplementation Does Not Affect Nonfasting Serum Lipid and Glucose Concentrations of Offspring at 4 Years of Age in a Follow-Up of a Randomized Controlled Clinical Trial in Mexico. J Nutr. 2017 Feb;147(2):242-247. doi: 10.3945/jn.116.238329. Epub 2016 Dec 21.
- Ramakrishnan U, Gonzalez-Casanova I, Schnaas L, DiGirolamo A, Quezada AD, Pallo BC, Hao W, Neufeld LM, Rivera JA, Stein AD, Martorell R. Prenatal supplementation with DHA improves attention at 5 y of age: a randomized controlled trial. Am J Clin Nutr. 2016 Oct;104(4):1075-1082. doi: 10.3945/ajcn.114.101071. Epub 2016 Sep 7.
- Gonzalez-Casanova I, Rzehak P, Stein AD, Garcia Feregrino R, Rivera Dommarco JA, Barraza-Villarreal A, Demmelmair H, Romieu I, Villalpando S, Martorell R, Koletzko B, Ramakrishnan U. Maternal single nucleotide polymorphisms in the fatty acid desaturase 1 and 2 coding regions modify the impact of prenatal supplementation with DHA on birth weight. Am J Clin Nutr. 2016 Apr;103(4):1171-8. doi: 10.3945/ajcn.115.121244. Epub 2016 Feb 24.
- Ramakrishnan U, Stinger A, DiGirolamo AM, Martorell R, Neufeld LM, Rivera JA, Schnaas L, Stein AD, Wang M. Prenatal Docosahexaenoic Acid Supplementation and Offspring Development at 18 Months: Randomized Controlled Trial. PLoS One. 2015 Aug 11;10(8):e0120065. doi: 10.1371/journal.pone.0120065. eCollection 2015.
- Gonzalez-Casanova I, Stein AD, Hao W, Garcia-Feregrino R, Barraza-Villarreal A, Romieu I, Rivera JA, Martorell R, Ramakrishnan U. Prenatal Supplementation with Docosahexaenoic Acid Has No Effect on Growth through 60 Months of Age. J Nutr. 2015 Jun;145(6):1330-4. doi: 10.3945/jn.114.203570. Epub 2015 Apr 29.
- Escamilla-Nunez MC, Barraza-Villarreal A, Hernandez-Cadena L, Navarro-Olivos E, Sly PD, Romieu I. Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in children. Chest. 2014 Aug;146(2):373-382. doi: 10.1378/chest.13-1432.
- Hernandez E, Barraza-Villarreal A, Escamilla-Nunez MC, Hernandez-Cadena L, Sly PD, Neufeld LM, Ramakishnan U, Romieu I. Prenatal determinants of cord blood total immunoglobulin E levels in Mexican newborns. Allergy Asthma Proc. 2013 Sep-Oct;34(5):e27-34. doi: 10.2500/aap.2013.34.3688.
- Stein AD, Wang M, Rivera JA, Martorell R, Ramakrishnan U. Auditory- and visual-evoked potentials in Mexican infants are not affected by maternal supplementation with 400 mg/d docosahexaenoic acid in the second half of pregnancy. J Nutr. 2012 Aug;142(8):1577-81. doi: 10.3945/jn.112.162461. Epub 2012 Jun 27.
- Imhoff-Kunsch B, Stein AD, Martorell R, Parra-Cabrera S, Romieu I, Ramakrishnan U. Prenatal docosahexaenoic acid supplementation and infant morbidity: randomized controlled trial. Pediatrics. 2011 Sep;128(3):e505-12. doi: 10.1542/peds.2010-1386. Epub 2011 Aug 1.
- Stein AD, Wang M, Martorell R, Neufeld LM, Flores-Ayala R, Rivera JA, Ramakrishnan U. Growth to age 18 months following prenatal supplementation with docosahexaenoic acid differs by maternal gravidity in Mexico. J Nutr. 2011 Feb;141(2):316-20. doi: 10.3945/jn.110.128215. Epub 2010 Dec 22. Erratum In: J Nutr. 2011 Sep;141(9):1762.
- Imhoff-Kunsch B, Stein AD, Villalpando S, Martorell R, Ramakrishnan U. Docosahexaenoic acid supplementation from mid-pregnancy to parturition influenced breast milk fatty acid concentrations at 1 month postpartum in Mexican women. J Nutr. 2011 Feb;141(2):321-6. doi: 10.3945/jn.110.126870. Epub 2010 Dec 22.
- Ramakrishnan U, Stein AD, Parra-Cabrera S, Wang M, Imhoff-Kunsch B, Juarez-Marquez S, Rivera J, Martorell R. Effects of docosahexaenoic acid supplementation during pregnancy on gestational age and size at birth: randomized, double-blind, placebo-controlled trial in Mexico. Food Nutr Bull. 2010 Jun;31(2 Suppl):S108-16. doi: 10.1177/15648265100312S203.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2005
Primary Completion (Actual)
January 3, 2013
Study Completion (Actual)
August 16, 2014
Study Registration Dates
First Submitted
March 25, 2008
First Submitted That Met QC Criteria
March 25, 2008
First Posted (Estimate)
March 28, 2008
Study Record Updates
Last Update Posted (Actual)
June 7, 2022
Last Update Submitted That Met QC Criteria
June 6, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- IRB00024976
- 5R01HD043099 (U.S. NIH Grant/Contract)
- 5R03HD087606 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Turku University HospitalUniversity of TurkuCompleted
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Hopital Antoine BeclereUnknown
Clinical Trials on DHA
-
University of New MexicoNational Center for Research Resources (NCRR)TerminatedPregnancy | Randomized Clinical Trial | Docosahexaenoic AcidUnited States
-
University of Alabama at BirminghamMead Johnson NutritionNot yet recruitingPremature | Infant Malnutrition | Nutrition Disorder, Infant | Light-For-Dates With Signs of Fetal MalnutritionUnited States
-
Pontificia Universidad Catolica de ChileCompletedObesity | Body CompositionChile
-
SCF PharmaCompleted
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitCompletedHealthy | Pharmacokinetics | Drug CombinationThailand
-
National Institute of Diabetes and Digestive and...Completed
-
Hospices Civils de LyonCompleted
-
DSM Nutritional Products, Inc.SynteractHCRCompleted
-
University of Kansas Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedUse and Dose of Prenatal DHA SupplementationUnited States